Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00892944 |
The purpose of this study is to determine if AZD2516 binds to mGluR5 receptors in the brain. This will then help to make accurate predictions of efficacy and dosing in the future development programme.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: AZD2516 |
Phase I |
Study Type: | Interventional |
Study Design: | Basic Science, Open Label, Single Group Assignment, Pharmacokinetics Study |
Official Title: | An Open Label Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2516 After Oral Administration to Healthy Subjects |
Estimated Enrollment: | 6 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | September 2009 |
Arms | Assigned Interventions |
---|---|
1: Experimental
AZD2516
|
Drug: AZD2516
Fractionated single oral dose
|
Ages Eligible for Study: | 20 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca Clinical Study Information | : 800-236-9933 | information.center@astrazeneca.com |
Contact: AstraZeneca Information, (Outside US) | 001-800-236-9933 |
Sweden | |
Research Site | Recruiting |
Stockholm, Sweden |
Principal Investigator: | Ingemar Bylesjo, MD, PhD | AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden |
Study Director: | Michael O'Malley | AstraZeneca R&D, Södertälje, Sweden |
Responsible Party: | AstraZeneca ( MSD ) |
Study ID Numbers: | D2080C00009 |
Study First Received: | April 28, 2009 |
Last Updated: | May 4, 2009 |
ClinicalTrials.gov Identifier: | NCT00892944 History of Changes |
Health Authority: | Sweden: Medical Products Agency |
Positron Emission Tomography Phase 1 Healthy volunteers AZD2516 |
Healthy |